Paroxetine Hydrochloride Enteric-coated Sustained-release Tablets
Formulation (FDF) · Sustained-release Tablets · 12.5mg; 25mg
Formulation (FDF)Confidentiality：Public
- INN / Generic Name
- Paroxetine Hydrochloride Enteric-coated Sustained-release Tablets
- Dosage Form
- Sustained-release Tablets
- Strength
- 12.5mg; 25mg
- Therapy Area
- Others > Psychiatry
- Indication
- Major depressive disorder; panic disorder; social anxiety disorder; premenstrual dysphoric disorder
- Current Status
- Official FDF licensing catalog (UB205)
- GMP Certification
- US - FDA; CN - NMPA
- CEP
- No
- DMF Type
- —
- Stability Data
- —
- BE Required
- Not required / waivable
- Registration Pathway
- Registered (market rights transferable / DCP·NP per market)
- MOQ
- On request
- Lead Time
- On request
- Price Range
- On request
HS Code
3004.903 customs bills on file
Registrable Markets
United States
Process / Sequence / Exact Price
- Process Summary
- —
- Exact Price